Presentation and Webcast on Tuesday, May 13 at 10:00 a.m. Pacific
Time/1:00 p.m. Eastern Time
ANN ARBOR, Mich.--(BUSINESS WIRE)--
Esperion Therapeutics, Inc. (NASDAQ: ESPR) today announced the Company
will present at the 2014 Bank of America Merrill Lynch Healthcare
Conference in Las Vegas, Nev. Tim M. Mayleben, president and chief
executive officer, will provide updates on the company on Tuesday, May
13 at 10:00 a.m. Pacific Time/1:00 p.m. Eastern Time.
A live, listen-only webcast of the presentation can be accessed on the
investor relations section of the Esperion website at investor.esperion.com/events.
A webcast replay of the call will be available approximately one hour
after completion of the call and will be archived on the Company's
website for approximately 90 days following the event.
About Esperion Therapeutics
Esperion Therapeutics, Inc. is a clinical stage biopharmaceutical
company focused on developing and commercializing first-in-class, oral,
low-density lipoprotein cholesterol (LDL-C) lowering therapies for the
treatment of patients with hypercholesterolemia and other
cardiometabolic risk markers. ETC-1002, Esperion's lead product
candidate, is a unique, first-in-class, orally available, once-daily
small molecule designed to lower LDL-cholesterol levels and avoid the
side effects associated with the currently-available LDL-cholesterol
lowering therapies. ETC-1002 is being developed primarily for patients
intolerant of statins with elevated levels of LDL-cholesterol. Phase 2b
clinical trials for ETC-1002 are currently underway and build upon a
successful and comprehensive Phase 1 and Phase 2 program. For more
information, please visit www.esperion.com.
Media Contact:
W2O Group
Elliot Fox
212.257.6724
efox@w2ogroup.com
or
Investor
Contact:
Westwicke Partners
Jordan Kohnstam
443.450.4189
jordan.kohnstam@westwicke.com
Source: Esperion Therapeutics, Inc.
News Provided by Acquire Media